Case Studies
Demonstrated expertise of Newland Global Group’s (NGG) advisory work
NGG taps its unparalleled internal and external ecosystem of experts, relationships, access, and industry intelligence to ensure that our clients achieve their goals. NGG is committed to crafting precedent-setting deals driven by our clients’ ideas, interests, and opportunities. Our goal is to help our clients achieve their ambitions.
NGG’s specialists amalgamate business acumen and profound sector knowledge with technical know-how and state-of-the-art analytic tools so that clients stay in front of the issues and make the best decisions. We have the workforce and capabilities to execute clients’ decisions – beginning right with the strategy, through seamless execution, to tangible results.
We analyse the current plan and prepare for the future by assisting our clients in seizing prospective opportunities. We are proud to share how we have helped our clients achieve their business-driven goals.
NGG is advising Noxopharm (NOX) on commercialising and licensing their IP to deliver specialised onco-care in India
Noxopharm is an Australian publicly-listed (ASX:NOX) clinical-stage drug development company. The clinical-stage drug candidate is Veyonda® (previously known as NOX-66). Veyonda® is a first-in-class, dual-acting cytotoxic and immuno-oncology drug candidate designed to enhance the effectiveness and safety of both chemotherapy and radiotherapy. At one level, Veyonda® enhances the cancer-killing effect of standard chemotherapy and radiotherapy, thereby enabling lower doses of these toxic therapies to be used. At another level, it seeks to activate the body’s innate immune cell function to attack those cancer cells that have survived the initial treatment. Veyonda® appears to work across the broad spectrum of cancers. The ultimate aim is to harness the body’s immune system to inflict damage on ALL cancer cells in the body, eradicating most, if not all cancer cells to produce long-term remission or even a curative outcome in what is known as an abscopal effect. An abscopal effect is where radiotherapy is applied to just the one lesion and triggers a response in all other non-irradiated lesions.
NGG was engaged by NOX to assist its entry into India. NGG prepared a detailed report for NOX, which shared New India’s growth opportunities in the health sector and provided market insights on India’s Cancer Care, specifically focusing on Prostate Cancer, and opportunities to build strategic partnerships with public and private organisations.
NGG is supporting NOX’s India goals and in helping it to explore, enter and expand in the Indian market, focusing on commercialising and licensing its expertise and IP, and setting an example towards strong Australia-India Bio-Tech/Health Sector engagement.